SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Goldman Sachs upgrade to Buy, citing Palantirs sovereign-AI and customized-software opportunities, coincided with a breakout to fresh highs. Bulls celebrate the momentum and speculate about a short squeeze, while skeptics warn that the valuation is stretched and the rally could reverse.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Repeated analyst price-target cuts amid a steep pullback are driving debate over APPs valuation and volatile price action. Bulls cite the companys cash generation and ad-growth potential and are watching for a recovery into Q3 earnings, while others remain wary of further downside and legal concerns.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

DOG, a Bitcoin-native Runes memecoin, is drawing attention through community promotion and dip-buying, with traders speculating that Bitcoin strength or Rune-related momentum could support a rebound. Skeptics counter that weak liquidity and volume, price declines, and limited exchange access make the bullish hype risky.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopifys partnership with Metas Muse to enable AI-agent purchases through Shop Pay is fueling interest, with bulls seeing a new commerce channel and skeptics questioning how quickly it can be monetized. Traders are also debating whether the sharp rally can continue amid volatility and resistance near recent highs.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRXs high-volume rally is being linked by traders to founder Patrick Soon-Shiongs scheduled oncology fireside chat, where he is expected to discuss trial progress, as well as anticipation around bladder-cancer regulatory milestones. Speculation about a partnership, a connection to the NIH cancer-vaccine initiative, and a possible short squeeze is circulating, but those claims are unconfirmed.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics MSToronto presentation schedule is drawing attention, particularly the late-breaking oral presentation of initial azer-cel findings in progressive MS alongside BRIUMVI trial data. Traders see the presentation selection as encouraging, but emphasize that it is not proof of positive results and debate whether the pipeline catalysts will overcome the stocks choppy trading.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded by Keyvan Mohajer, Majid Seyed Emami and James M. Hom on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHounds steep decline to repeated 52-week lows is driving attention, with traders pointing to dilution and uncertainty over profitability and managements execution despite company expansion and partnership headlines. The community is split between expectations of further downside and speculation about a short squeeze, with many looking to the next earnings report for evidence of progress.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

Reports that Michael Burry disclosed a stake in QXO have sparked a rebound after a prolonged selloff, with traders speculating about short covering. Some see the move as a turning point, while others remain focused on pressure from high rates, soft housing and construction demand, and integrating recent acquisitions.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

A reported NIH-backed push to accelerate personalized cancer vaccines is drawing attention to Mercks role in the field, including its V940 partnership with Moderna and promising melanoma-trial results. Traders see the initiative as supportive of Mercks oncology prospects, though some caution that a research push does not guarantee near-term revenue.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs agreement to acquire Grain Managements 800 MHz spectrum has stoked fears that Starlink Mobile could become a stronger competitor to T-Mobile and other U.S. carriers, driving a sharp selloff in telecom shares. Traders disagree over whether the deal signals a serious long-term threat or an overreaction, citing the spectrums limits and the infrastructure needed to build a competing network.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's Why You Should Add URGN Stock to Your Portfolio Now

UroGen's Zusduri sales surge, Jelmyto revenues and advancing pipeline assets strengthen its shift toward a commercial growth story.

Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet

The consensus price target hints at a 27.1% upside potential for Urogen Pharma (URGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

UroGen Pharma Stock Falls 5% After Signing Deals With IntraGel Therapeutics

(RTTNews) - Shares of UroGen Pharma Ltd. (URGN) are falling about 5 percent in Thursday morning trading after the company entered into an equity investment agreement and a strategic Option and Research License Agreement with IntraGel Therapeutics...

IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies

IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released...

Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice

Does Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates

Urogen Pharma (URGN) delivered earnings and revenue surprises of +26.32% and +16.42%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Insmed (INSM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Did CVS, URGN, CCK Stocks Hit 52-Week Highs Today? 

Equity

Investors showed confidence in healthcare improvements, strong biotech patents, and rising packaging demand. 


UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run

Key PointsAccording to this Form 4 filing, the CMO of UroGen Pharma sold 10,000 shares at $40.00 per share, totaling $400,000 in transaction proceeds...

Urogen Pharma (URGN) is a Great Momentum Stock: Should You Buy?

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

UroGen Pharma Ltd

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

$URGN according to my source, the sales team made their numbers and Moore for ZUSDURI expect to see over 90 million for the quarter

$URGN 
BO price 5-6bb. Easy 3 figs.
J&J a likely suitor. Better than PFE or NOV. EMA approval should be coming. 
Great pipeline. 
Sooo

Bob Dunn

$URGN I am a believer that this co will be taken out above $100 sometime next year.  So this heavy drop, 1 month before ER call, could be funds positioning themselves for a big rise.  Shake the tree, collect the fruit, then eat.

Kevin Roger

$URGN 
Sure looks like manipulation to me. 
This should do nothing but go up to analysts PTs before a drop like this. 
12.78% SI may have something to do with it.
Buy'em 
Extremely

$URGN What could have possibly happened to warrant this?  Will we be getting bad news AH?

$URGN should be able to get a buy in around mid to low 30s in the next couple days I would think. Would be a great long hold at that price

Feed

News

Sentiment

Earnings

Fundamentals

Info

URGN UroGen Pharma Ltd

Fundamentals

Latest URGN News